Market research
0F1.F NanoString Technologies, Inc
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- 77.2
- Dividend yield
- Not available
- Beta
- 1.05
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- US63009R1095
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- 77.2
- Dividend yield
- Not available
- Beta
- 1.05
About
About NanoString Technologies, Inc
NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bank
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 0F1.F discussion.
5 years, 6 months ago
NanoString Technologies, Inc is currently in a long term downtrend where the price is trading 0.9% below its 200 day moving average.
From a valuation standpoint, the stock is 98.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 21.9.
NanoString Technologies, Inc's total revenue sank by 1.8% to $36M since the same quarter in the previous year.
Its net income has dropped by 195.9% to $-23M since the same quarter in the previous year.
Finally, its free cash flow grew by 54.9% to $-12M since the same quarter in the previous year.
Based on the above factors, NanoString Technologies, Inc gets an overall score of 2/5.